Vericel Corp (VCEL) stock

VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value

$57.42−2.03 (-3.41%)

Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –

Vericel EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Vericel's EV/EBITDA was 92.4× on Nov 11, 2026, against 111.5× a year earlier. Over the last 4 years it ranged from 55.7× to 895.0×, with a median of 241.3×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	92.4×	−6.4
2025	Dec 31, 2025	98.9×	−560.7
2024	Dec 31, 2024	659.6×	+176.2
2022	Jan 31, 2022	483.4×	−53.7
2021	Dec 31, 2021	537.1×	−357.9
2020	Dec 31, 2020	895.0×	–

Where these numbers come from

Parsed from the XBRL in Vericel's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Oct 16, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VCEL.

Compare: VCEL vs ORGO · VCEL vs IOVA · VCEL vs MESO · VCEL vs KRYS · VCEL vs ADMA

Revenue growth25.3% · median 6.3%

Gross margin74.5% · median 60.9%

Operating margin8.3% · median 11.0%

Net margin10.3% · median -38.4%

Company	Revenue	Growth
ADMA	$519.15M	+6.3%
KRYS	$470.03M	+26.0%
IOVA	$378.98M	+51.3%
ORGO	$352.05M	-24.3%
VCEL	$324.17M	+25.3%
MESO	$7.50M	-26.5%

Company

Next earnings (est.): Feb 25, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 398
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 887359

Advertisement
300 × 250

See a number that looks wrong?